scholarly journals Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: A single-blinded pilot study

2016 ◽  
Vol 34 (4) ◽  
pp. 177-179 ◽  
Author(s):  
Narumol Silpa-Archa ◽  
Sunatra Nitayavardhana ◽  
Kanchalit Thanomkitti ◽  
Leena Chularojanamontri ◽  
Supenya Varothai ◽  
...  
Keyword(s):  
Pilot Study ◽  
Mometasone Furoate ◽  
Efficacy And Safety ◽  
Tacrolimus Ointment

627-P: Efficacy and Safety of Allogeneic Platelet Rich Plasma in Treatment of Diabetic Patients with Lower Limb Ulcers: A Pilot Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 627-P
Author(s):  
WUQUAN DENG ◽  
MIN HE ◽  
BING CHEN ◽  
YU MA ◽  
DAVID ARMSTRONG ◽  
...  
Keyword(s):  
Pilot Study ◽  
Lower Limb ◽  
Platelet Rich Plasma ◽  
Diabetic Patients ◽  
Efficacy And Safety

scholarly journals Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study

2021 ◽  
Vol 4 (3) ◽  
Author(s):  
Azin Ayatollahi ◽  
Ansieh Samadi ◽  
Ayda Bahmanjahromi ◽  
Reza M. Robati
Keyword(s):  
Pilot Study ◽  
Efficacy And Safety

scholarly journals Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Silvio Bellino ◽  
Paola Bozzatello ◽  
Camilla Rinaldi ◽  
Filippo Bogetto
Keyword(s):  
Borderline Personality Disorder ◽  
Pilot Study ◽  
Personality Disorder ◽  
Adverse Events ◽  
Mechanism Of Action ◽  
Severity Index ◽  
Borderline Personality ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Dsm Iv

Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials.

Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study

Dermatology ◽  
2015 ◽  
Vol 230 (4) ◽  
pp. 308-313 ◽  
Author(s):  
Hesham Zaher ◽  
Heba I. Gawdat ◽  
Rehab A. Hegazy ◽  
Marwa Hassan
Keyword(s):  
Pilot Study ◽  
Alopecia Areata ◽  
Mometasone Furoate
Sign in / Sign up

Export Citation Format

Share Document